Endogenous erythropoietin concentrations and association with retinopathy of prematurity and brain injury in preterm infants

PLoS One. 2021 Jun 2;16(6):e0252655. doi: 10.1371/journal.pone.0252655. eCollection 2021.

Abstract

Background: Endogenous erythropoietin (EPO) concentrations vary widely in preterm infants and may be associated with perinatal risk factors and neurological outcomes. Erythropoietin is elevated in fetal hypoxia but is also a potential neuroprotectant.

Methods: In a prospective study of 27 infants ≤ 30 weeks gestation, serum erythropoietin concentrations were measured during the first month of life, on day 1 and weeks 1, 2, and 4, and related to perinatal risk factors and outcomes including retinopathy of prematurity and cerebral injury evaluated near term-equivalent post menstrual age using magnetic resonance imaging with quantitative scoring.

Results: Lower birth weight was associated with higher EPO concentrations throughout the first 2 weeks of life (r = -0.6, p < 0.01). Higher day 1 and week 1 EPO concentrations were associated with lower Apgar score at 1 minute (r = - 0.5) and 5 minutes (r = -0.7), respectively (p < 0.01). Higher day 1 EPO concentrations and 2-week area under the curve were associated with increased risk (p = 0.01) and severity (r = 0.5, p < 0.02) of retinopathy of prematurity. Higher EPO concentrations at 2 weeks were associated with increased total brain injury score (r = 0.5, p < 0.05).

Conclusion: Elevated endogenous erythropoietin concentrations in the first two weeks of life are associated with lower birth weight and increased risk of adverse outcomes.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Age Factors
  • Apgar Score
  • Brain Injuries / metabolism*
  • Erythropoietin / metabolism*
  • Female
  • Humans
  • Infant, Low Birth Weight / physiology
  • Infant, Newborn
  • Infant, Newborn, Diseases
  • Infant, Premature / metabolism*
  • Infant, Premature, Diseases
  • Male
  • Pregnancy
  • Prospective Studies
  • Retinopathy of Prematurity

Substances

  • EPO protein, human
  • Erythropoietin